You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 29, 2024

CLINICAL TRIALS PROFILE FOR CALCIFEDIOL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Calcifediol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01574027 ↗ Efficacy of Vitamin D in Colorectal Cancer Chemoprevention Completed University of Illinois at Chicago Phase 2 2008-04-01 Vitamin D's ability to prevent colorectal cancer (CRC) has been suspected for nearly 30 years, but has never been directly studied in humans. The biologically active version of vitamin D, 1,25(OH)2D3, cannot be readily used in humans because of its tendency to cause serum calcium levels to rise. In contrast, 25(OH)D3 (ie calcifediol) does not have this side effect. The investigators previous research suggests that the enzyme necessary to convert 25(OH)D3 (calcifediol) into active 1,25(OH)D3 is present in cells lining the large intestine (colon). Aberrant crypt foci (ACF) are very small (ie microscopic) collections of abnormally shaped cells that are a commonly used marker of CRC risk. Screening colonoscopy at UIC routinely uses methods that allow ACF counting to be done as a part of standard practice. ACF's are not fixed, like polyps or cancers, but can disappear as a person's risk for developing CRC decreases. The investigators propose giving patient's with 10 or more ACF's 25(OH)D3 (calcifediol) or placebo, and determining if there is a drug-dependant decrease in ACF number. The primary objective is to determine whether 25(OH)D3 (calcifediol) supplementation, compared to placebo, causes significant reduction of ACF number from baseline levels. The primary endpoint will be change in ACF number.
NCT01651000 ↗ Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Completed OPKO IP Holdings II, Inc. Phase 3 2012-09-01 This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
NCT01704079 ↗ Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Completed OPKO IP Holdings II, Inc. Phase 3 2012-11-01 This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
NCT01939977 ↗ Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed AbbVie Phase 4 2014-01-01 To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation.
NCT01939977 ↗ Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed Effice Servicios Para la Investigacion S.L. Phase 4 2014-01-01 To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation.
NCT01939977 ↗ Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed Fundación Senefro Phase 4 2014-01-01 To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Calcifediol

Condition Name

Condition Name for Calcifediol
Intervention Trials
Vitamin D Deficiency 10
Hyperparathyroidism, Secondary 4
Secondary Hyperparathyroidism Due to Renal Causes 3
Chronic Kidney Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Calcifediol
Intervention Trials
Vitamin D Deficiency 12
Hyperparathyroidism, Secondary 8
Hyperparathyroidism 8
Neoplasm Metastasis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Calcifediol

Trials by Country

Trials by Country for Calcifediol
Location Trials
United States 80
Spain 10
Bulgaria 1
Italy 1
Slovakia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Calcifediol
Location Trials
Illinois 8
California 7
Massachusetts 4
Florida 3
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Calcifediol

Clinical Trial Phase

Clinical Trial Phase for Calcifediol
Clinical Trial Phase Trials
Phase 4 5
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Calcifediol
Clinical Trial Phase Trials
Completed 15
Recruiting 5
Not yet recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Calcifediol

Sponsor Name

Sponsor Name for Calcifediol
Sponsor Trials
OPKO Health, Inc. 6
OPKO Ireland Global Holdings Ltd. 5
OPKO IP Holdings II, Inc. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Calcifediol
Sponsor Trials
Other 19
Industry 18
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.